Acute Coronary Syndrome Market Report 2026

The acute coronary syndrome market size has grown strongly in recent years. It will grow from $10.43 billion in 2025 to $11.06 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, limited awareness of early acs symptoms, expansion of hospital cardiac facilities, availability of conventional medications, growing geriatric population.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $14.51 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to development of novel anticoagulants and statins, increasing adoption of minimally invasive cardiac procedures, expansion of specialty clinics, rising government initiatives for heart disease prevention, technological advancements in imaging and stress testing. Major trends in the forecast period include rising adoption of early diagnostic techniques for acs, increased use of percutaneous coronary intervention (pci), growing awareness of acs risk factors and prevention, expansion of hospital cardiac care units, advancements in oral and parenteral acs treatments.

Increasing healthcare expenditures are expected to drive the growth of the acute coronary syndrome market. Healthcare expenditures refer to the total spending on healthcare services, products, and activities within a defined period, typically at individual, community, national, or global levels. Rising healthcare expenditures are fueled by factors such as the increasing prevalence of chronic diseases, aging populations, advancements in medical technology, and higher demand for advanced treatments and healthcare services. Higher healthcare spending supports growth in the acute coronary syndrome sector by enabling the development of improved diagnostic technologies, advanced therapies, and comprehensive treatment options, addressing the growing need for cardiovascular care. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, reported that healthcare expenditure in the UK reached approximately $362.08 billion (£292 billion) in 2023, reflecting a nominal increase of 5.6%. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditures are driving the growth of the acute coronary syndrome market.

Major companies operating in the acute coronary syndrome market are focusing on developing innovative drugs to treat acute coronary syndrome and maintain their market position. Advances in drug development can enhance the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which received approval from the Food and Drug Administration (FDA), a US-based government agency. Lodoco is the first anti-inflammatory atheroprotective cardiovascular treatment designed to reduce the risk of stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

In May 2023, Avertix Medical Inc., a US-based company specializing in implantable patient alerting systems for acute coronary syndrome (ACS), merged with BIOS Acquisition Corporation for approximately $195 million. Through this merger, Avertix aims to expand its commercial portfolio and continue developing its innovative products, providing patients and healthcare providers with advanced tools for ACS management. BIOS Acquisition Corporation is a US-based incorporated blank check company.

Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

North America was the largest region in the acute coronary syndrome market in 2025. The regions covered in the acute coronary syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute coronary syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute coronary syndrome market by increasing costs for imported medications, cardiac imaging devices, and PCI-related equipment. Segments such as percutaneous coronary intervention (PCI) and advanced diagnostic tools are most affected, particularly in north america, europe, and asia-pacific regions. The tariffs have led to higher treatment costs and procurement delays. On the positive side, they have encouraged local manufacturing of cardiac care devices and medications, supporting regional self-sufficiency and innovation.

The acute coronary syndrome market research report is one of a series of new reports that provides acute coronary syndrome market statistics, including acute coronary syndrome industry global market size, regional shares, competitors with a acute coronary syndrome market share, detailed acute coronary syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the acute coronary syndrome industry. This acute coronary syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute coronary syndrome (ACS) refers to a group of clinical conditions caused by a sudden reduction in blood flow to the heart. Symptoms of ACS include chest pain or discomfort (angina), shortness of breath, dizziness, and other signs of heart-related distress. Treatment for acute coronary syndrome aims to quickly relieve symptoms, minimize heart damage, and prevent further complications.

The main types of acute coronary syndrome are non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and unstable angina. NSTEMI is a type of heart attack in which one or more coronary arteries are partially or completely blocked, reducing blood supply to the heart muscle. Treatments include medications, statins, beta-blockers, ACE inhibitors, anticoagulants, and others, while diagnostic methods include stress tests, blood tests, imaging, and more. Administration routes include oral and parenteral. These treatments are used by end users such as hospitals, specialty clinics, and others.

The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.